ReviewFrontiers in pain research (Lausanne, Switzerland)2021
Modulation of Glia-Mediated Processes by Spinal Cord Stimulation in Animal Models of Neuropathic Pain.
Review in Frontiers in pain research (Lausanne, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 17 citations in OpenAlex.
- Twelve-Month results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain.Pain practice : the official journal of World Institute of Pain · 2021Trial
- Early high‑frequency spinal cord stimulation modulates the ROS/p38 MAPK/NF‑κB and CXCL10/CXCR3 pathways to alleviate neuropathic pain and promote spinal cord injury repair.International journal of molecular medicine · 2026Article
- State of the Art in Neuromodulation or Spinal Cord Stimulation Therapy.Journal of clinical medicine · 2026Review
- Molecular and Cellular Mechanisms of Spinal Cord Stimulation: Linking Dorsal Horn Circuits, Glia, and ECAP-Guided Therapy.International journal of molecular sciences · 2026Review
- Open and closed loop differential target multiplexed spinal cord stimulation in patients with persistent spinal pain syndrome type II: protocol for a one year European multicenter cohort study (ENDLESS).Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Mechanisms and Applications of Conductive Biomaterials in Spinal Cord Injury Repair.Biomaterials research · 2026Review
- Network Meta-analysis of Randomized Controlled Trials Assessing Neuromodulation Therapies for Painful Diabetic Neuropathy.Neurology and therapy · 2025Article
- Review
- Article
- Navigating the Neuroimmunomodulation Frontier: Pioneering Approaches and Promising Horizons-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Spinal Cord Stimulation for Intractable Chronic Limb Ischemia: A Narrative Review.Journal of cardiovascular development and disease · 2024Review
- Lumbosacral spinal proteomic changes during PAR4-induced persistent bladder pain.Neuroscience letters · 2024Article
- Answering Big Questions in Pain Medicine.Cureus · 2023Review
- Article
- Exploring gene signatures and regulatory networks in a rat model of sciatica: implications and validation in neuropathic pain.Frontiers in molecular neuroscience · 2023Article
- Narrative review of current neuromodulation modalities for spinal cord injury.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Effects of central nervous system electrical stimulation on non-neuronal cells.Frontiers in neuroscience · 2022Review
- Pain modulation in the spinal cord.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Neuromodulation therapies for diabetic neuropathy: mechanisms, efficacy, and impacts on nerve health: a narrative review.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glial cells play an essential role in maintaining the proper functioning of the nervous system. They are more abundant than neurons in most neural tissues and provide metabolic and catabolic regulation, maintaining the homeostatic balance at the synapse. Chronic pain is generated and sustained by the disruption of glia-mediated processes in the central nervous system resulting in unbalanced neuron-glial interactions. Animal models of neuropathic pain have been used to demonstrate that changes in immune and neuroinflammatory processes occur in the course of pain chronification. Spinal cord stimulation (SCS) is an electrical neuromodulation therapy proven safe and effective for treating intractable chronic pain. Traditional SCS therapies were developed based on the gate control theory of pain and rely on stimulating large Aβ neurons to induce paresthesia in the painful dermatome intended to mask nociceptive input carried out by small sensory neurons. A paradigm shift was introduced with SCS treatments that do not require paresthesia to provide effective pain relief. Efforts to understand the mechanism of action of SCS have considered the role of glial cells and the effect of electrical parameters on neuron-glial interactions. Recent work has provided evidence that SCS affects expression levels of glia-related genes and proteins. This inspired the development of a differential target multiplexed programming (DTMP) approach using electrical signals that can rebalance neuroglial interactions by targeting neurons and glial cells differentially. Our group pioneered the utilization of transcriptomic and proteomic analyses to identify the mechanism of action by which SCS works, emphasizing the DTMP approach. This is an account of evidence demonstrating the effect of SCS on glia-mediated processes using neuropathic pain models, emphasizing studies that rely on the evaluation of large sets of genes and proteins. We show that SCS using a DTMP approach strongly affects the expression of neuron and glia-specific transcriptomes while modulating them toward expression levels of healthy animals. The ability of DTMP to modulate key genes and proteins involved in glia-mediated processes affected by pain toward levels found in uninjured animals demonstrates a shift in the neuron-glial environment promoting analgesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.